Correction,Biometrical Journal

当前位置： X-MOL 学术 › Biom. J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Correction
Biometrical Journal ( IF 1.3 ) Pub Date : 2021-06-04 , DOI: 10.1002/bimj.202170054

April 23, 2021

Dear Editors,

Biometrical Journal

In the paper by Fujikawa et al. entitled “A Bayesian basket-trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability” published in 2020, Biometrical Journal, 62, 330–338, DOI: 10.1002/bimj.201800404, we wish to correct the following:

(i) Table 1

TABLE 1. Posterior probabilities for the basket trial of the BRAF inhibitor vemurafenib for three cases

	NSCLC	Colorectal vemurafinib	Colorectal vemurafinib cetuximab	Cholangio	ECD or LCH	Anaplastic thyroid carcinoma	Glioma	MM	PXA	Other
No. of responders/No. of observations	8/19	0/10	1/26	1/8	6/14	2/7	0/8	0/5	3/4	3/14
Case (i): Independent analysis	0.76	0.01	<0.01	0.12	0.75	0.43	0.02	0.08	0.95	0.17
Case (ii): Borrowing-information analysis based on proposed design	0.80	<0.01	<0.01	<0.01	0.80	0.37	<0.01	<0.01	0.92	0.15
Case (iii): Borrowing-information analysis based on Simon's design	0.95	0.03	<0.01	0.15	0.90	0.41	0.05	0.11	0.82	0.24

NSCLC, nonsmall cell lung cancer; ECD, Erdheim-Chester disease; LCH, Langerhans cell histiocytosis; MM, multiple myeloma; PXA, pleomorphic xanthoastrocytoma.

(ii) The fifth sentence in the section 3 of “The posterior probabilities for the borrowing-information analysis based on our design (case (ii)) were larger than those for the independent analysis (case (i)) for NSCLC, ECD or LCH, anaplastic thyroid carcinoma, and much smaller than”

The revised text is as follows:

“The posterior probabilities for the borrowing-information analysis based on our design (case (ii)) were larger than those for the independent analysis (Case (i)) for NSCLC, ECD or LCH, and much smaller than”

(iii) A submitted R code “Table _1.R”

We have attached the revised R code “Table_1.R” (as Supporting Information).

The correct Table 1 is as given below.

We have corrected the probabilities for Case (ii) for NSCLC, ECD or LCH, Anaplastic thyroid carcinoma, and Other.

Sincerely,

Satoshi Teramukai

Department of Biostatistics

Graduate School of Medical Science

Kyoto Prefectural University of Medicine

中文翻译：

更正

2021 年 4 月 23 日

亲爱的编辑们，

生物识别杂志

在 Fujikawa 等人的论文中。题为“基于响应概率的后验分布之间的相似性跨层借用信息的贝叶斯篮式试验设计”，发表于 2020 年，Biometrical Journal，62, 330–338，DOI：10.1002/bimj.201800404，我们希望更正以下内容：

(一) 表 1

表 1. BRAF 抑制剂 vemurafenib 篮子试验三个病例的后验概率

	非小细胞肺癌	结直肠vemurafinib	大肠威罗非尼西妥昔单抗	乔拉焦	ECD 或 LCH	甲状腺未分化癌	胶质瘤	毫米	PXA	其他
响应者数量/数量观察结果	8/19	0/10	1/26	1/8	6/14	2/7	0/8	0/5	3/4	3/14
情况（一）：独立分析	0.76	0.01	<0.01	0.12	0.75	0.43	0.02	0.08	0.95	0.17
情况（二）：基于提议设计的借款信息分析	0.80	<0.01	<0.01	<0.01	0.80	0.37	<0.01	<0.01	0.92	0.15
情况（三）：基于西蒙设计的借款信息分析	0.95	0.03	<0.01	0.15	0.90	0.41	0.05	0.11	0.82	0.24